Monoclonal Antibody Infliximab Biosimilar
Monoclonal antibody infliximab biosimilar is a biotechnologically produced chimeric antibody targeting TNF-alpha, used to treat inflammatory conditions like Crohn's disease. It is produced by recombinant DNA technology and is a therapeutic biological product. This product falls under tariff item 3002.12.00 as an immunological product, per Chapter 30 note 2.
Import Duty Rates by Country of Origin
| Origin Country | MFN Tariff | Surtaxes | Total Effective Rate |
|---|---|---|---|
| 🇨🇳China | Free | — | Free |
| 🇲🇽Mexico | Free | — | Free |
| 🇺🇸United States | Free | — | Free |
| 🇩🇪Germany | Free | — | Free |
| 🇯🇵Japan | Free | — | Free |
More Specific Codes
This product may fall under a more specific subheading:
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If the product is a monoclonal antibody
Monoclonal antibodies are specifically classified under subheading 3002.14.
If the product is put up in measured doses for retail sale
Medicaments in measured doses are classified under heading 30.04.
Not sure which classification is right?
The Tariff Assistant works through the GRI rules on your specific product to reach the right tariff item — and can price the duty on it in the same conversation.
Import Tips & Compliance
• Provide evidence of the product's biosimilar status and Health Canada approval
• Ensure the product is not classified as a diagnostic reagent, which would be excluded from Chapter 30
• Verify that the product is not put up in measured doses for retail sale, which could shift classification to heading 30.04
Related Products under Tariff item 3002.12.00
Anti-Rh(D) Immunoglobulin Injection
Anti-Rh(D) immunoglobulin injection is a blood fraction containing antibodies against the Rh(D) antigen, derived from human plasma. It is administered prophylactically to prevent hemolytic disease of the newborn in Rh-negative mothers. This product is classified under tariff item 3002.12.00 as an antiserum prepared for therapeutic use.
Botulinum Toxin Type A Immune Globulin
Botulinum toxin type A immune globulin is an antitoxin derived from human plasma fractions containing antibodies against botulinum toxin. It is used to treat infant botulism by neutralizing the toxin. This product falls under tariff item 3002.12.00 as an immunological blood fraction for therapeutic neutralization.
Botulism Antitoxin (Trivalent, Equine)
Botulism Antitoxin (Trivalent, Equine) is an antiserum derived from equine plasma containing antibodies that neutralize botulinum neurotoxins A, B, and E. It is used therapeutically for the treatment of botulism poisoning. This product falls under tariff item 3002.12.00 as an antiserum prepared for therapeutic uses.
Cryoprecipitated Antihemophilic Factor from Human Plasma
Cryoprecipitated Antihemophilic Factor from Human Plasma is a human plasma fraction rich in factor VIII, fibrinogen, and von Willebrand factor. It is prepared by thawing frozen plasma at 1-6°C and used to treat hemophilia A and fibrinogen deficiencies. This product falls under tariff item 3002.12.00 as a blood fraction for therapeutic use.
Cytomegalovirus (CMV) Hyperimmune Globulin
Cytomegalovirus (CMV) hyperimmune globulin is a plasma fraction enriched with CMV-specific antibodies, used to prevent CMV infection in transplant patients. It is prepared from pooled human plasma of donors with high antibody titers. This product is classified under tariff item 3002.12.00 as a blood fraction prepared for prophylactic use.
Cytomegalovirus Immune Globulin Intravenous (CMV-IGIV)
Cytomegalovirus Immune Globulin Intravenous (CMV-IGIV) is a purified immunoglobulin fraction derived from human plasma of donors with high CMV antibody titers. It is used prophylactically to prevent CMV infection in transplant patients. This product falls under tariff item 3002.12.00 as a blood fraction prepared for therapeutic or prophylactic uses.